Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

9.59
+0.14001.48%
Post-market: 9.57-0.0201-0.21%19:59 EDT
Volume:13.59M
Turnover:128.12M
Market Cap:2.49B
PE:2.88
High:9.75
Open:9.61
Low:9.18
Close:9.45
Loading ...

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Business Wire
·
28 Mar

Barclays Sticks to Its Buy Rating for Organon (OGN)

TIPRANKS
·
10 Mar

May Health Appoints Seasoned Medtech Executive, Colby Holtshouse, as President and CEO

THOMSON REUTERS
·
10 Mar

Organon announes results from analysis of Phase 3 ADORING 3 study

TIPRANKS
·
10 Mar

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Business Wire
·
08 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
06 Mar

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Simply Wall St.
·
17 Feb

Organon & Co. Navigates Growth Amidst Challenges

TIPRANKS
·
17 Feb

Organon Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
15 Feb

Organon & Is Maintained at Overweight by Barclays

Dow Jones
·
14 Feb

Bank of America Securities Reaffirms Their Sell Rating on Organon (OGN)

TIPRANKS
·
14 Feb

Morgan Stanley Keeps Their Hold Rating on Organon (OGN)

TIPRANKS
·
14 Feb

Organon price target lowered to $24 from $26 at Barclays

TIPRANKS
·
14 Feb

BUZZ-Organon rises on Q4 profit beat

Reuters
·
14 Feb

Stock Track | Organon & Co (OGN) Soars 8.98% on Strong Q4 Results and Optimistic 2025 Outlook

Stock Track
·
13 Feb

Organon & Co reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Feb

Organon's Q4 Adjusted Earnings Rise, Revenue Declines; 2025 Sales Guidance Set

MT Newswires Live
·
13 Feb

Organon Expects 2025 Sales Of $6.125B-$6.325B Versus Consensus Of $6.471B

Benzinga
·
13 Feb

Organon & Co - Q4 2024 Net Income of $109 Million, $0.42 per Diluted Share

THOMSON REUTERS
·
13 Feb

Organon & Co - 2025 Revenue Guidance Range of $6.125 Billion - $6.325 Billion

THOMSON REUTERS
·
13 Feb